Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112603 · ClinicalTrials.gov registry record · Phase 3
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT03112603 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 330 participants.
The verdict
NCT03112603, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Interventions
- DRUG Ruxolitinib
- DRUG Mycophenolate mofetil (MMF)
- DRUG Extracorporeal photopheresis (ECP)
- DRUG Low-dose methotrexate (MTX)
- DRUG mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03112603
The ClinicalTrials.gov registry entry for NCT03112603 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ruxolitinib is the first listed.
NCT03112603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03112603 about?
NCT03112603 is a clinical study titled "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)". The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
What is the current status of trial NCT03112603?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2017-06-29. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT03112603?
The interventions under investigation include: Ruxolitinib (DRUG), Mycophenolate mofetil (MMF) (DRUG), Extracorporeal photopheresis (ECP) (DRUG), Low-dose methotrexate (MTX) (DRUG), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) (DRUG).
Who is sponsoring clinical trial NCT03112603?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.